AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04579614 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Impact of Performance Feedback and Variable Goal Setting on Flu Vaccination Success Rates of Providers
Description: A given provider will be involved in the study for a maximum of 6 months. This will involve, at the most frequent, the delivery of weekly performance feedback.~The performance feedback will be delivered using standard approaches already in place in the organization and there will not be a period of seeking out participants for enrollment.~Providers will receive performance feedback bi-weekly for the duration of the study period.
Study NCT04579614 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Impact of Performance Feedback and Variable Goal Setting on Flu Vaccination Success Rates of Providers
Description: A given provider will be involved in the study for a maximum of 6 months. This will involve, at the most frequent, the delivery of weekly performance feedback.~The performance feedback will be delivered using standard approaches already in place in the organization and there will not be a period of seeking out participants for enrollment.~Providers will receive performance feedback bi-weekly for the duration of the study period.
Study NCT03994757 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MRBI
Description: The activities content is designed according to the children's daily routine and goals. It mainly involves bathing activities, eating activities, dressing activities, game activities, social and communication activities, and according to the needs of parents. In the treatment room, after the therapist and parents discuss the intervention methods and suggestions, they will demonstrate the intervention strategies and methods, and let the parents practice the practice, and the therapist will guide them. After discussing with parents, the therapist will give parents a homework related to children's daily routine, let the parents implement at home, and discuss with parents and record before each intervention.
Study NCT03994757 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Traditional treatment was directly performed for children in the treatment room by the therapist. The activity content was designed according to the children's goals. After each end of treatment, therapist will give parents a homework related to traditional treatments, let the parents perform at home, and know the parents' performance at home and record before each treatment begins.
Study NCT06303414 — intervention group
Intervention type: PROCEDURE
Intervention: Carotid Endarterectomy (CEA)
Description: Carotid endarterectomy (CEA) Surgeons follow the contemporary guideline combined with their experience and preference in order to ultimately select what is best suited for the patient and choose between CEA, CAS and Hybrid Sugery. Patients will receive 100 mg of aspirin or 75 mg of clopidogrel daily starting from at least 72 h prior to the CEA procedure and continued receiving the medication indefinitely. General anesthesia is recommended for CEA, although the use of standard or eversion endarterectomy, and a shunt or patch, is left to the discretion of the surgeon.
Study NCT06303414 — intervention group
Intervention type: PROCEDURE
Intervention: Carotid Artery Stenting (CAS)
Description: Carotid artery stenting (CAS) Surgeons follow the contemporary guideline combined with their experience and preference in order to ultimately select what is best suited for the patient and choose between CEA, CAS and Hybrid Sugery. Patients will be given 100 mg of aspirin plus 75 mg of clopidogrel daily for at least 3 days before the CAS procedure and for 90 days after the procedure. They will receive a daily dose of 100 mg aspirin or 75 mg clopidogrel thereafter. For the CAS procedure, general anesthesia and predilation prior to stent placement are recommended. Use of an embolic protection device is advised for all patients who undergo CAS.
Study NCT06303414 — intervention group
Intervention type: PROCEDURE
Intervention: Hybrid Surgery
Description: Hybrid Surgery Surgeons follow the contemporary guideline combined with their experience and preference in order to ultimately select what is best suited for the patient and choose between CEA, CAS and Hybrid Sugery. Patients will be given 100 mg of aspirin plus 75 mg of clopidogrel daily for at least 5 days before the hybird surgery procedure. If they had stenting procedure, they will receive a daily dose of 100 mg aspirin and 75 mg clopidogrel thereafter. If not, they will take either 100mg aspirin or 75mg clopidogrel daily for life.
Study NCT03438188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Practice Quit Attempt
Description: Smokers will be studied under 2 conditions: smoking as usual and during a 4 day practice quit attempt.
Study NCT03229967 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 16S rRNA stool microbiome sequencing.
Description: This is an observational cohort that will undergo gut microbiome sequencing.
Study NCT01419938 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Light therapy and Cognitive behaviour therapy
Description: Light therapy every morning during 30 minutes for two weeks. CBT for 90 to 120 minutes weekly during four weeks.
Study NCT01419938 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Light therapy
Description: Light therapy every morning during 30-45 minutes for two weeks.
Study NCT00912223 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic Stem Cell Transplant
Description: NOTE: The - sign is the number of days before the transplant and the + sign is the number of days after the transplant.~The conditioning regimen will consist of the following:~* Rituxan 375 mg/m\^2 on Day -13~* Rituxan 1000 mg/m\^2 on Days -6, +1, and +8~* Fludarabine 30 mg/m\^2 on Days -5 to -3~* Cyclophosphamide 750 mg/m\^2 on Days -5, -4, -3~Day 0 will be the day of the transplant.~The GVHD prophylaxis will consist of the following:~* Tacrolimus .09 mg/kg/po (Day -2 thru Day +180). Doses will be adjusted to maintain blood levels of 5-15 ng/mL.~* Methotrexate 5 mg/m\^2 (Days +1, +3, and +6). Unrelated donor recipients will receive a fourth dose on Day +11.
Study NCT02196077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BFF MDI 320/9.6 μg
Description: Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 320/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
Study NCT02196077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BFF MDI 160/9.6 μg
Description: Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 160/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
Study NCT03193749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone Hydrochloride
Description: Starting (loading) dose 400 mg PO once a day for 10 days. Maintainance dose 200 mg PO once a day for at least 6 months, up to 24 months
Study NCT03193749 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Matching placebo for tablets of 200 mg of Amiodarone
Study NCT01906281 — intervention group
Intervention type: OTHER
Intervention: Blood analyse, arthrocentesis, ultrasound examination
Study NCT02119806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzodiazepine
Description: Receive as premedication in the Benzodiazepine group.
Study NCT02119806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Receive as maintenance in the Benzodiazepine group. Can receive as premedication in the Non-Benzodiazepine group. Receive as maintenance in the Non-Benzodiazepine group.
Study NCT02196077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BFF MDI 80/9.6 μg
Description: Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 80/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
Study NCT02196077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BD MDI 320 μg
Description: Budesonide metered dose inhaler (BD MDI) 320 μg; PT008 administered as 2 inhalations, twice daily (BID)
Study NCT02196077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF MDI 9.6 μg
Description: Formoterol fumarate metered dose inhaler (FF MDI) 9.6 μg; PT005 administered as 2 inhalations, twice daily (BID)
Study NCT02119806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Receive postoperatively in the Benzodiazepine group. Can receive as premedication in the Non-Benzodiazepine group. Receive postoperatively in the Non-Can receive as premedication in the Non-Benzodiazepine group.
Study NCT03962322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weaning TDI
Description: Patients will be subjected to a spontaneous breathing test (Cpap 5), that consists in applying a positive end-expiratory pressure of 5 cm H2O for 20 minutes.~A tissue doppler evaluation will then be performed by analyzing the diaphragmatic displacement velocity during inspiration and expiration and calculating the speed of muscles displacement and other derived index of muscle function in the modality of ventilation which precedes the trial, during the SBT and after extubation.
Study NCT04115852 — intervention group
Intervention type: BEHAVIORAL
Intervention: fmri
Description: functional magnetic resonance imaging
Study NCT04690478 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic remote blood pressure monitor
Description: Remote blood pressure management group through remote blood pressure management the platform realizes functions such as automatic upload of patient measurement data, intelligent analysis, and early warning reminders
Study NCT04690478 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ordinary household electronic sphygmomanometer
Description: One group is distributed a set of ordinary household electronic sphygmomanometer, and the blood pressure is recorded by themselves at home following routine community office follow-up
Study NCT04690478 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Office electronic sphygmomanometer
Description: One group follows routine community office follow-up and uses office electronic sphygmomanometer to measure blood pressure
Study NCT01764308 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3
Description: 1200mg twice a day for 24 weeks
Study NCT01764308 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Omega-3
Description: 1200mg twice a day for 24 weeks
Study NCT02219386 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 1. Deep dry needling
Description: Deep dry needling and stretch. The intervention included DDN of every active MTrP found in the trapezius muscle using a 4 cm x 0.32 mm acupuncture needle as described by Simons et al. (Simons et al., 1999). Once the needle was inserted into the MTrP previously marked by the blinded assessor, local twitch responses (LTRs) were obtained by using Hong's fast-in and fast-out technique, which involves rapid movements of the needle in and out of the MTrP. After four LTRs, the needle was withdrawn and the area was disinfected with alcohol again (Simons et al., 1999). Then, passive stretch was performed on the trapezius muscle.
Study NCT02219386 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Group 1. Deep dry needling
Description: Deep dry needling and stretch. The intervention included DDN of every active MTrP found in the trapezius muscle using a 4 cm x 0.32 mm acupuncture needle as described by Simons et al. (Simons et al., 1999). Once the needle was inserted into the MTrP previously marked by the blinded assessor, local twitch responses (LTRs) were obtained by using Hong's fast-in and fast-out technique, which involves rapid movements of the needle in and out of the MTrP. After four LTRs, the needle was withdrawn and the area was disinfected with alcohol again (Simons et al., 1999). Then, passive stretch was performed on the trapezius muscle.
Study NCT02219386 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: group 2. Passive analitical stretch (performed in both groups)
Study NCT00028522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R(+)XK469
Description: Given IV
Study NCT02007278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vildagliptin and metformin (combination)
Description: vildagliptin and metformin combination therapy as 50mg/850mg bid or 50mg/1000mg bid
Study NCT02007278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Study NCT02007278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study NCT02826252 — intervention group
Intervention type: DRUG
Intervention: Iloprost,(Ventavis, BAYQ6256)
Description: Ventavis (Iloprost) nebulizer solution for inhalation as 10 μg/mL (V10) and 20 μg/mL (V20).
Study NCT02826252 — intervention group
Intervention type: DEVICE
Intervention: I-Neb AAD system
Description: Nebulizer, allows digital recording of inhalation data such as doses, inhalations per day and duration of inhalation (per day) etc.
Study NCT03474094 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pre-operative radiotherapy followed by 2 cycles of atezolizumab then surgery
Description: W1,W2, W3, W4 \& W5: RADIOTHERAPY. A 3-dimensional conformal RT (3D-CRT) with photons ≥ 6MV will be realized based on the acquisition of a CT-scan performed in treatment position. Intensity modulated RT (IMRT), volumetric modulated arc therapy (VMAT) and tomotherapy are authorized.~W6 and W9: ATEZOLIZUMAB IV INJECTION. 2 injections of 1200 mg of atezolizumab with a 3-week interval~W11: SURGERY. Surgery should be performed as per Institutional practice by a surgeon with appropriate training in the treatment of sarcoma. The primary aim of surgery is to completely excise the tumor with a margin of normal tissue commonly accepted as 1 cm soft tissue, or equivalent
Study NCT01764308 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 4 tablets twice a day for 24 weeks
Study NCT01764308 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 tablets twice a day for 24 weeks
Study NCT03474094 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 2 cycles of atezolizumab followed by surgery then post-operative radiotherapy
Description: W1 and W4: ATEZOLIZUMAB IV INJECTION. 2 injections of 1200 mg of atezolizumab with a 3-week interval~W6: SURGERY Surgery should be performed as per Institutional practice by a surgeon with appropriate training in the treatment of sarcoma. The primary aim of surgery is to completely excise the tumor with a margin of normal tissue commonly accepted as 1 cm soft tissue, or equivalent~W7, W8, W9, W10 \& W11: RADIOTHERAPY A 3-dimensional conformal RT (3D-CRT) with photons ≥ 6MV will be realized based on the acquisition of a CT-scan performed in treatment position. Intensity modulated RT (IMRT), volumetric modulated arc therapy (VMAT) and tomotherapy are authorized.
Study NCT03360110 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phoebe test lens
Description: Daily disposable contact lens
Study NCT03474094 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Pre-operative radiotherapy followed by surgery then 2 cycles of atezolizumab.
Description: W1,W2, W3, W4 \& W5: RADIOTHERAPY A 3-dimensional conformal RT (3D-CRT) with photons ≥ 6MV will be realized based on the acquisition of a CT-scan performed in treatment position. Intensity modulated RT (IMRT), volumetric modulated arc therapy (VMAT) and tomotherapy are authorized.~W6: SURGERY Surgery should be performed as per Institutional practice by a surgeon with appropriate training in the treatment of sarcoma. The primary aim of surgery is to completely excise the tumor with a margin of normal tissue commonly accepted as 1 cm soft tissue, or equivalent~W11 and W14: ATEZOLIZUMAB IV INJECTION. 2 injections of 1200 mg of atezolizumab with a 3-week interval
Study NCT01163006 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Polydextrose and soluble gluco fibre
Description: Polydextrose and soluble gluco fibre
Study NCT01163006 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polydextrose and soluble gluco fibre
Description: Polydextrose and soluble gluco fibre
Study NCT00502853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: 1000mg iv on days 1 and 15
Study NCT00502853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 10-25mg/week
Study NCT01361867 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Robot-induced perturbations
Description: A robotic system is used to generate mechanical perturbations and study how subjects generate motor adaptations in response to the mechanical perturbations.
Study NCT02407587 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cochlear implants
Description: PET scans for the mature patients with unilateral cochlear implants and preserved hearing~4 states and each state will be repeated 3 times Cochlear implant only Residual hearing only Combination of implant and residual hearing No auditory stimulation
Study NCT03609190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: i.v. infusion of 0.25 mg/kg S-ketamine over 40 min
Study NCT03609190 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: i.v. infusion of NaCl over 40 min
Study NCT01472978 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: metronidazole
Description: Metronidazole, 500 mg three times a for 10 days
Study NCT01472978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metronidazole
Description: Metronidazole, 500 mg three times a for 10 days
Study NCT01687855 — intervention group
Intervention type: DEVICE
Intervention: Ultrafast Magnetic Resonance Imaging
Description: MRI was performed with a 1.5 superconducting magnet (Gyroscan Intera type, Philips Co. Holland) in a posterior and anterior neck coil. The sequence used to perform the ultrafast MRI was a fast gradient- echo plus sequence. Technical parameters included: echo time, 12 msec; repetition time, 2.3 msec; flap angle, 250; matrix, 192 × 512; section thickness, 7 mm. The imaging time per slice for this sequence was 0.92 sec. A total of 120 consecutive images were obtained as a single section, with a total imaging time of 110.4 seconds. MRI scanning was carried out with the subject first asleep, then whilst awake after 20 minutes in quiet respiration. All images were inputted to the PACS workstation.
Study NCT02570230 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NSS
Description: NSS infusion
Study NCT02570230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine 0.2 mg/kg/hr intravenous infusion
Study NCT03836456 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Stress Resilience Training
Description: Mindfulness is a form of cognitive training that cultivates self-regulative ability and enhances resilience
Study NCT03836456 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Enhancement Program
Description: This is a validated active control developed to serve as a control for mindfulness-based studies.
Study NCT02408952 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary Care Physician
Description: The screening, brief intervention and referral to treatment is delivered by the Primary Care Physician
Study NCT02408952 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Medicine Specialist
Description: The screening, brief intervention and referral to treatment is delivered by the Behavioral Medicine Specialist.
Study NCT04262960 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device: active CPAP
Description: auto-PAP with pressure between 4 and 20 cm H2O will be administered to randomized patients
Study NCT04262960 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Device: sham-CPAP
Description: The sham-CPAP will be fixed in the lowest pressure (4cmH2) and modified as recommended by Farré et al, with pressure that no greater than 1cm H2O.
Study NCT02085226 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Creative Engagement Intervention
Description: The CEI has 5 component stages which map the participant's journey with the Artist~1. Meeting with Artist, discuss interests, stroke and explore initial creative goals.~2. Introduction to materials and mark making to create interpretations of established images.~3. From mark making and interpretations to developing personal project ideas.~4. Turning personal project ideas into creative finished pieces.~5. Review of completed work, mounting and display of work, future plans.~It is recognised that participants will progress differently. Components may be repeated or retuned to or may be addressed simultaneously. Participants may progress rapidly and so move from stage 5 back to stages 2, 3 or 4 to progress new work or experience new materials or processes.
Study NCT02085226 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Portfolio Group
Description: The Portfolio group will receive conventional rehabilitation activity at each site. In addition, to control for effects of art related attention received by the intervention group, after baseline assessment and randomisation, this group will receive from the research assistant, a portfolio of work produced by previous participants of the Tayside CEI, with details of community programmes that people with stroke can attend after hospital discharge. Participants will be invited to view the portfolio during their stay. Prior to outcome assessment, the research assistant will visit participants again to answer questions and to discuss options for community programmes, if the person is interested.
Study NCT03340298 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fiber
Description: the intervention of different sources of dietary fibers
Study NCT04549623 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel end-tidal CO2 monitoring device
Description: Apart from SpO2 and respiratory motion monitoring, the EtCO2 monitoring device is used to detect CO2 from nose and mouth simultaneously.